Lupin gets USFDA nod to market chewable oral contraceptive

Published On 2016-01-09 07:03 GMT   |   Update On 2022-12-06 06:14 GMT
Advertisement
Drug major Lupin has received final approval from the US health regulator to market generic version of Warner Chilcott's oral contraceptive Generess Fe in the American market.

In a BSE filing, Lupin said it "has received final approval for its Kaitlib Fe Tablets from the United States Food and Drug Administration (USFDA) to market Warner Chilcott's Generess Fe Chewable Tablets", Lupin said in a BSE filing.

Quoting IMS MAT September 2015 sales data, Lupin said the tablets had US sales of USD 89.8 million.

The Mumbai-based firm has launched 9 products in the US market and received approvals for 20 products from the USFDA so far this fiscal.

The company added that its US subsidiary Lupin Pharmaceuticals Inc will commence promoting the product in the US shortly.

Lupin had recently received US health regulator's final approval to market Blisovi
oral contraceptive
tablets in different strengths in the American market.

Lupin has launched its Tri-Lo-Marzia tablets, an oral contraceptive drug, in the US market after getting approval from the American health regulator.

The Mumbai-based firm has launched nine products in the US the last fiscal and received approvals for 20 from the USFDA. Its cumulative abbreviated new drug application (ANDA) filings with the USFDA stood at over 220 with the company having received 131 approvals till date.
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News